BACKGROUND Recent reports showing the favorable role of patent foramen ovale (PFO) closure in patients with
Although PFO shows a variable degree of shunt amount and is reported to have a cumulative risk of stroke with atrial septal aneurysm, it remains elusive whether the potential benefit gained from device closure of a PFO can also be determined on the basis of the morphologic characteristics of the PFO. In our previous study, we observed that the anatomic features of the atrial septal abnormalities associated with PFO, as evaluated by transesophageal echocardiography (TEE), were quite diverse and that high-risk PFO as defined by TEE findings, including PFO size, the presence of an atrial septal aneurysm, or hypermobility, was useful in predicting stroke recurrence (19) . Considering the high prevalence of PFO in the general population and in patients with cryptogenic stroke, transcatheter device closure confined to patients with cryptogenic stroke and characteristic PFO morphology associated with a higher stroke recurrence rate would be a more appropriate approach to enhance the benefits of PFO closure. To test the hy- A standardized TEE protocol (19) was used to assess the morphologic characteristics of the atrial septum and right-to-left shunting through a high-risk PFO with agitated saline while the patient was at rest or while a Valsalva maneuver was being performed.
As described previously (19) , a high-risk PFO included (G) Some patients without a characteristic atrial septal aneurysm may show exaggerated motion of the atrial septum during the Valsalva maneuver, resulting in (H) septal excursion >10 mm and (I) a large PFO size (arrow). Ao ¼ aorta; LA ¼ left atrium; RA ¼ right atrium; TEE ¼ transesophageal echocardiography.
Follow-up MRI was recommended 6 months after randomization in both groups to diagnose asymptomatic ischemic stroke.
STATISTICAL ANALYSIS. On the basis of the results from a previous study (19) , we assumed the event rate at 24 months would be 4% in the PFO closure group and 15% in the medication-only group. It was estimated that 99 patients in each group were needed to detect this difference with a statistical power of 80%.
Expecting that approximately 10% of the patients would not return for follow-up, the total sample size was estimated to be 210 patients (105 patients per group) with a 2-sided alpha level of 0.05. Abbreviations as in Figure 1 .
patients. Follow-up echocardiography was performed in 1 patient with severe residual shunt 2 months later, and this study showed disappearance of the residual shunt.
Temporal changes of the medications prescribed in the 2 groups are summarized in Table 2 . Dualantiplatelet therapy was the most frequently chosen medication in both groups at 30 days after randomization, and this trend continued for up to 12 months in the medication-only group. However, in the combined PFO closure group, single-antiplatelet therapy became the most frequent strategy after 6 months, and 17% (8 of 47) of patients stopped medication after the PFO closure. At the beginning, warfarin was prescribed in 25% of the patients in the medication-only group, and anticoagulation therapy continued in more than 20% until 12 months after the randomization. Thus, anticoagulation therapy was more frequently used in the medication-only group 6 months after the randomization. Values are mean AE SD or n (%).
PFO ¼ patent foramen ovale. Table 3) .
DISCUSSION
In this trial of PFO closure in a selected group of patients who had experienced a recent cryptogenic ischemic stroke and had high-risk PFO defined as PFO with an associated atrial septal aneurysm, hypermobility, or large size, the rate of the primary endpoint, including recurrent ischemic stroke, was significantly lower with closure of the PFO in combination with medical therapy than with medical therapy alone.
This trial showed that 10 patients would need to be treated to avoid 1 stroke at 2 years. hazard ratio. Although the current trial had a lower than expected rate of patient recruitment, publication of consecutive clinical trials favoring PFO closure was the main reason that our research members decided on early termination of this trial; more specifically, the report of the CLOSE trial with stringent entry criteria similar to ours made our neurologists, the gate keepers of the current study, concerned about potential safety issues in maintaining this trial. In addition, because this trial was conducted in only 2 centers, potential selection bias of the enrolled patients cannot be completely excluded.
CONCLUSIONS
We have confirmed that the morphologic character- 
